Source: Eur Respir J 2015; 46: 862-865



Rating:

Share or cite this content

Citations should be made in the following way:
Ali Haider, Orchard Christopher, Mariveles Myril, Scott Sandra, Alshafi Khalid, Bilton Diana, Simmonds Nicholas. Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis. Eur Respir J 2015; 46: 862-865

Member's Comments

No comment yet.

Related content which might interest you: Challenges of providing care to adults with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 286-303 Year: 2014 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapy Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 A new paradigm for the management of children with cystic fibrosis at home: experiences from a Dutch cystic fibrosis clinic Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases Year: 2021 Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 486s Year: 2006 Does sputum induction improve Pseudomonas aeruginosa detection in cystic fibrosis? Source: Eur Respir J 2003; 22: Suppl. 45, 231s Year: 2003 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Biofilms and how to combat them: examples from cystic fibrosis Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Newborn screening for cystic fibrosis: opportunities and remaining challenges Source: Eur Respir Monogr 2014; 64: 65-76 Year: 2014 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014